Court of Appeals Ruling on Teva Copaxone® Patent Allows Mylan May 2014 Launch
PITTSBURGH, July 26, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. Court of Appeals for the Federal Circuit has reversed a district court's finding related to Teva's U.S. Patent 5,800,808 for Copaxone®, thereby invalidating the patent.
Mylan CEO Heather Bresch said, "We are very pleased with today's ruling and we expect that it will allow Mylan to launch its generic version of Copaxone® on May 25, 2014 upon expiration of Teva's Orange Book patents, subject to Mylan's final regulatory approval."
All other rulings by the district court have been affirmed.
This press release includes statements that constitute "forward-looking statements," including with regard to litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: strategies by competitors or other third parties to delay or prevent product sales; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.